Vicore Pharma extends research portfolio with new drug molecules
Vicore Pharma has today announced that it has developed new drug molecules that selectively stimulate the AT2 receptor (AT2R agonism) in the Renin-Angiotensin-System. Based on experience and learnings drawn from the company’s successful drug candidate, C21, the new molecules have been designed to address diseases in the metabolic and cardiovascular areas This pressrelease has been published in Swedish on January 24, 2017. On behalf of Vicore Pharma, Emeriti Bio—a Swedish company specialising in drug discovery—has designed and synthesized a new set of molecules using Vicore Pharma’s